OVERVIEW

25th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma is organized by Physicians' Education Resource, LLC (PER) and will be held from Feb 25 - 28, 2021.

Preconference Workshop:
CAR T Preconference Workshop at the PER® Winter Hematology® Meeting
Date and Time: Thursday, February 25, 2021 & 12:30 PM – 6:10 PM

Accreditation/
Credit Designation
Physicians' Education Resource®, LLC designates this live activity for a maximum of 21.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 21.75 Contact Hours.

This education activity will be submitted to the American Association of Nurse Practitioners for approval of up to 4.5 contact hours of accredited education.

CAR T Pre-Conference Workshop
To earn an additional 4.5 AMA PRA Category 1 Credits™, attend the CAR T Preconference Workshop.

Overview:
Now in its 25th year, the annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma provides practitioners who manage hematologic malignancies with the practical tools to translate emerging data into the best therapy for their patients, to personalize care according to patient and tumor characteristics, and to apply novel treatment strategies to improve patient outcomes.

They are pleased to continue expanded coverage on chimeric antigen receptor (CAR) T cells and other immune-based therapies in 2021. First, a full afternoon session on Thursday, February 25, 2021, will be dedicated to addressing advances in CAR T-cell therapy for hematologic malignancies, as well as other immune-based therapies and strategies to overcome treatment resistance. Next, sessions on Friday, Saturday, and Sunday will focus on methods to apply state-of-the-art treatment strategies in your clinical practice setting. This engaging and highly interactive meeting will provide ample opportunity for attendees to interact with internationally renowned experts in the management of leukemias, lymphomas, myeloma, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPNs), and benign hematologic malignancies. Our faculty will distill practice-changing evidence and recommend how to put this information into clinical context, so that you may apply the latest evidence to real-world patient-care scenarios. Proactive measures to mitigate and manage treatment-related toxicities associated with new cellular therapies will also be discussed. Finally, they will continue to provide expert opinion on how the value-based landscape will impact your clinical practice.

Interspersed throughout the meeting are sessions of Medical Crossfire®, a nationally recognized healthcare communication platform for debate, discussion, and peer exchange. These sessions will provide attendees with the opportunity to explore some of the most challenging clinical situations in the management of hematologic malignancies—treatment scenarios with multiple potential approaches.

This dynamic congress will inspire participants to reflect on and share the new information they have learned, and to apply these new practices in the clinical setting, with the ultimate goal of improving patient outcomes.

Hot Topics:
• How to apply newly approved agents in hematologic malignancies
• The latest developments in CAR T-cell therapy
• The increasing importance of genomics and molecular testing in hematologic malignancies
• How to cope with the emerging value-based care landscape

Benefits of Attending:
• Keep up-to-date with emerging and recently approved agents and approaches for patients with hematologic malignancies and benign hematologic disorders
• Learn about how molecular profiling and other emerging techniques for risk assessment can help optimize therapy for your patients
• Elevate your competence in managing treatment-related adverse events
• Network with your peers and internationally renowned experts in hematology/oncology